Journal article
Dosing, efficacy and safety of lenvatinb in the real‐world treatment of hepatocellular carcinoma: Results from a Canadian database
Abstract
Abstract Background and Aims A phase 3 trial showed lenvatinib to be effective and safe in the treatment of unresectable hepatocellular carcinoma (HCC), however, its performance in the real world and effect of dosing on survival are unclear. Methods From July 2018 to June 2020, HCC patients treated with lenvatinib from 10 Canadian cancer centres were included. Overall survival (OS) and progression‐free survival (PFS) were retrospectively …
Authors
Amaro CP; Allen MJ; Knox JJ; Tsang ES; Lim HJ; Lee‐Ying RM; Chan KW; Qian J; Meyers BM; Thawer A
Journal
Liver International Communications, Vol. 3, No. 3, pp. 119–127
Publisher
Wiley
Publication Date
September 2022
DOI
10.1002/lci2.59
ISSN
2994-1393